Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 10, 2011, Pages 2189-2199

  Samaiya, Misti ^a   Bakhshi, Sameer ^b   Shukla, Abhay A ^a   Kumar, Lalit ^b   Chauhan, Shyam S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Cathepsin L (CTSL); Chronic myeloid leukaemia (CML); K562 cells; Promoter methylation; Vascular endothelial growth factor (VEGF)

Indexed keywords

CATHEPSIN L; CYSTATIN C; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROMOTER REGION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN L; CYSTATIN C; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053239645     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01203.x     Document Type: Article

References (52)

1. Faderl S, Talpaz M, Estrov Z, et al Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999; 131: 207-19.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340: 1330-40.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824-30.
4. Kelliher MA, McLaughlin J, Witte ON, et al Induction of a chronic myelogenous leukemia -like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 1990;87: 6649-53.
5. Heisterkamp N, Jenster G, ten Hoeve J, et al Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344: 251-3.
6. Lugo TG, Pendergast AM, Muller AJ, et al Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990; 247: 1079-82.
7. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, et al Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia. 2002; 16: 1160-6.
8. Sun X, Li Y, Yu W, et al MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration. Leukemia. 2008; 22: 1053-6.
9. Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res. 1991; 51: 1478-81.
10. Dennemärker J, Lohmüller T, Mayerle J, et al Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene. 2010; 29: 1611-21.
11. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007; 6: 60-4.
12. Lankelma JM, Voorend DM, Barwari T, et al Cathepsin L, target in cancer treatment? Life Sci. 2010; 86: 225-33.
13. Gerber A, Wille a, Welte T, et al Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells. J Interferon Cytokine Res. 2001; 21: 11-9.
14. Gallardo E, de Andres I, Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol. 2001; 60: 847-55.
15. Collette J, Ulku AS, Der CJ, et al Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer. 2004; 112: 190-9.
16. Kim K, Cai J, Shuja S, et al Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas. Int J Cancer. 1998; 79: 324-33.
17. Gottesman MM, Sobel ME. Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA. Cell. 1980; 19: 449-55.
18. Keerthivasan S, Keerthivasan G, Mittal S, et al Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells. Gene. 2007; 399: 129-36.
19. Chauhan SS, Ray D, Kane SE, et al Involvement of carboxy-terminal amino acids in secretion of human lysosomal protease cathepsin L. Biochemistry. 1998; 37: 8584-94.
20. Trinkaus M, Vranic A, Dolenc VV, et al Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers. 2005; 20: 50-9.
21. Kayser K, Richter N, Hufnagl P, et al Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer. Anticancer Res. 2003; 23: 2767-72.
22. Foekens JA, Kos J, Peters HA, et al Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol. 1998; 16: 1013-21.
23. Niedergethmann M, Wostbrock B, Sturm JW, et al Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas. 2004; 29: 204-11.
24. Chauhan SS, Popescu NC, Ray D, et al Cloning, genomic organization, and chromosomal localization of human cathepsin L. J Biol Chem. 1993; 268: 1039-45.
25. Arora S, Chauhan SS. Identification and characterization of a novel human cathepsin L splice variant. Gene. 2002; 293: 123-31.
26. Albano F, Specchia G, Anelli L, et al Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes Cancer. 2003; 36: 353-60.
27. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975; 45: 321-34.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-54.
29. Divya, Chhikara P, Mahajan VS, et al Differential activity of cathepsin L in human placenta at two different stages of gestation. Placenta. 2002; 23: 59-64.
30. Pfaffl, MW. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res. 2001; 29: 2002-7.
31. Jean D, Rousselet N, Frade R. Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene. 2006; 25: 1474-84.
32. Vidovic A, Jankovic G, Colovic M, et al The proto-oncogene expression varies over the course of chronic myeloid leukemia. Hematology. 2008; 13: 34-40.
33. Janssen JJ, Klaver SM, Waisfisz Q, et al Identification of genes potentially involved in disease transformation of CML. Leukemia. 2005; 19: 998-1004.
34. He R, Liu B, Yang C, et al Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence. Cancer Gene Ther. 2003; 10: 879-86.
35. Musolino C, Calabro L, Bellomo G, et al Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol. 2002; 69: 159-63.
36. Mayerhofer M, Valent P, Sperr WR, et al BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002; 100: 3767-75.
37. Krauth MT, Simonitsch I, Aichberger KJ, et al Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am J Clin Pathol. 2004; 121: 473-81.
38. Muller-Esterl W, Fritz H, Kellermann J, et al Genealogy of mammalian cysteine proteinase inhibitors. Common evolutionary origin of stefins, cystatins and kininogens. FEBS Lett. 1985; 191: 221-6.
39. Konduri SD, Yanamandra N, Siddique K, et al Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene. 2002; 21: 8705-12.
40. Vigneswaran N, Wu J, Muller S, et al Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells - a preliminary study. Pathol Res Pract. 2005; 200: 753-62.
41. Rivenbark AG, Livasy CA, Boyd CE, et al Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp Mol Pathol. 2007; 8: 188-97.
42. Sato N, Maitra A, Fukushima N, et al Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003; 63: 4158-66.
43. Shin TH, Paterson AJ, Grant JH 3rd, et al 5-Azacytidine treatment of HA-A melanoma cells induces Sp1 activity and concomitant transforming growth factor alpha expression. Mol Cell Biol. 1992; 12: 3998-4006.
44. Hagiwara H, Sato H, Ohde Y, et al 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. Br J Pharmacol. 2008; 153: 1373-81.
45. Aguayo A, Kantarjian H, Manshouri T, et al Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96: 2240-5.
46. Di Raimondo F, Palumbo GA, Molica S, et al Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 2001; 106: 177-83.
47. Korkolopoulou P, Viniou N, Kavantzas N, et al Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia. 2003; 17: 89-97.
48. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653-60.
49. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003; 3: 422-33.
50. Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol. 1990; 1: 127-36.
51. Rebbaa A, Chu F, Sudha T, et al The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res. 2009; 29: 4473-81.
52. Shimada N, Ohno-Matsui K, Iseki S, et al Cathepsin L in bone marrow-derived cells is required for retinal and choroidal neovascularization. Am J Pathol. 2010; 176: 2571-80.